Is evantumumab suitable for all cancer types?

Amivantamab is a monoclonal antibody specifically designed to target epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (c-Met). Its main function is to inhibit the activity of these two receptors, thereby preventing the proliferation of cancer cells. It is mainly used to treat non-small cell lung cancer (NSCLC), especially patients with EGFR mutations or c-Met amplification. However, evantumumab is not suitable for all types of cancer. Its application range is more specific and needs to meet specific cancer types and molecular characteristics.

The main indication for evantumumab is non-small cell lung cancer (NSCLC), especially in patients with EGFR mutations (including T790M mutations) or c-Met amplification. EGFR and c-Met are two receptors that are highly expressed or overactive in a variety of tumor types and play important roles in the growth and survival of cancer cells. Evantumumab enhances anti-tumor effects by targeting both receptors simultaneously. Therefore, for these specific molecular features, evantumumab showed higher therapeutic efficacy.

Although evantumumab has achieved remarkable results in non-small cell lung cancer, it is not suitable for all types of cancer. Its effects are primarily dependent on specific mutations or overexpression of EGFR and c-Met, so the therapeutic efficacy of evantumumab is significantly reduced in cancers without these molecular signatures. For example, it is not applicable to most gastric cancers, liver cancers, colorectal cancers, etc., because the roles of EGFR and c-Met in these cancers are not as prominent as in lung cancer. In addition, it lacks efficacy against other receptor-driven tumors.

The indications for evantumumab mainly depend on the patient's molecular testing results. Therefore, before starting treatment, doctors usually conduct relevant genetic testing to confirm the presence of EGFR mutations or c-Met amplifications. Clinical studies have shown that evantuzumab acts on some EGFR and c-MetIt has shown good results in patients with non-small cell lung cancer that is positive, but the results are not ideal for other types of cancer or patients who lack these molecular characteristics. Therefore, the use of evantumumab must be individualized according to the patient's specific molecular profile.

xa0

Reference materials:https://www.rybrevant.com/